SYNlogic Reports Q1 2026 Financial Results with Increased Net Income and Restructuring Efforts

SYNlogic, Inc. reported its financial results for the first quarter of 2026, revealing a net income of $681,000, or $0.05 per share, compared to a net income of $317,000, or $0.03 per share, in the same period of 2025. The company did not generate any revenue during the quarter, consistent with its previous fiscal periods. Total operating expenses increased to $1.32 million from $898,000 year-over-year, primarily driven by higher general and administrative costs and restructuring charges. Research and development expenses rose to $49,000 from $22,000, reflecting additional storage costs for product candidates.

The company’s balance sheet as of March 31, 2026, showed total assets of $14.61 million, a decrease from $15.45 million at the end of 2025. Cash and cash equivalents were reported at $14.1 million, down from $14.67 million. Current liabilities decreased significantly to $2.06 million from $3.58 million, largely due to a reduction in the purchase warrant liability, which fell from $2.57 million to $694,000. The accumulated deficit stood at $442 million, slightly improved from $442.66 million at the end of the previous year.

Strategically, SYNlogic has undergone significant changes, including the discontinuation of its Synpheny-3 trial for its lead product candidate, labafenogene marselecobac (SYNB1934), in February 2024. This decision was based on an internal review indicating that the trial was unlikely to meet its primary endpoint. Following this, the company initiated a corporate restructuring that resulted in a drastic reduction of its workforce, leaving only one full-time employee. The company is currently exploring strategic alternatives, including potential mergers or sales, and has engaged consultants to assist in this process.

Operationally, SYNlogic's restructuring has led to a focus on cost management, with total restructuring charges increasing to $206,000 in Q1 2026 from $40,000 in Q1 2025. The company has not reported any significant changes in customer counts or product adoption rates, as it has not generated product revenue since its inception. The company’s employee headcount has been significantly reduced, reflecting its shift in operational strategy.

Looking ahead, SYNlogic expects its current cash reserves to be sufficient to fund operations for at least the next 12 months. The company will continue to incur costs related to its strategic review process and anticipates that general and administrative expenses may rise as it explores various strategic alternatives. However, there can be no assurance that these efforts will result in successful transactions or enhance stockholder value.